Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer

BACKGROUND: Advanced non-small-cell lung cancer (NSCLC) harbours many genetic aberrations that can be targeted with systemic treatments. Whole-genome sequencing (WGS) can simultaneously detect these (and possibly new) molecular targets. However, the exact added clinical value of WGS is unknown. OBJE...

Descripción completa

Detalles Bibliográficos
Autores principales: Simons, Martijn J. H. G., Retèl, Valesca P., Ramaekers, Bram L. T., Butter, Rogier, Mankor, Joanne M., Paats, Marthe S., Aerts, Joachim G. J. V., Mfumbilwa, Zakile A., Roepman, Paul, Coupé, Veerle M. H., Uyl-de Groot, Carin A., van Harten, Wim H., Joore, Manuela A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599348/
https://www.ncbi.nlm.nih.gov/pubmed/34405371
http://dx.doi.org/10.1007/s40273-021-01073-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599348/
https://www.ncbi.nlm.nih.gov/pubmed/34405371
http://dx.doi.org/10.1007/s40273-021-01073-y

Ejemplares similares